Fibrosis: from mechanisms to medicines

Neil C. Henderson, Florian Rieder, Thomas A. Wynn

Research output: Contribution to journalArticlepeer-review

Abstract

Fibrosis can affect any organ and is responsible for up to 45% of all deaths in the industrialized world. It has long been thought to be relentlessly progressive and irreversible, but both preclinical models and clinical trials in various organ systems have shown that fibrosis is a highly dynamic process. This has clear implications for therapeutic interventions that are designed to capitalize on this inherent plasticity. However, despite substantial progress in our understanding of the pathobiology of fibrosis, a translational gap remains between the identification of putative antifibrotic targets and conversion of this knowledge into effective treatments in humans. Here we discuss the transformative experimental strategies that are being leveraged to dissect the key cellular and molecular mechanisms that regulate fibrosis, and the translational approaches that are enabling the emergence of precision medicine-based therapies for patients with fibrosis.

Original languageEnglish
Pages (from-to)555-566
JournalNature
Volume587
Issue number7835
DOIs
Publication statusPublished - 25 Nov 2020

Fingerprint Dive into the research topics of 'Fibrosis: from mechanisms to medicines'. Together they form a unique fingerprint.

Cite this